FDA approves GSK's Advair Diskus 250/50 for COPD patients with chronic bronchitis
GlaxoSmithKline's Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol inhalation powder 50 mcg) has been approved by the US FDA for the maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis.
GlaxoSmithKline's Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol inhalation powder 50 mcg) has been approved by the US FDA for the maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis.
'We anticipate that this approval will be welcome news for patients and physicians,' said Chris Viehbacher, president, US Pharmaceuticals. 'Advair Diskus is an important new treatment option for this condition and it offers a new approach to treating this widespread and complex lung disease.'